MammoSite uses an approach called brachytherapy -- an internal treatment in which an inflatable balloon is surgically inserted into the breast.

A thin tube is attached to the balloon and for 10 minutes two times a day a radioactive seed is inserted into the balloon that fills the tumor cavity.

The treatment, which FDA approved in 2002, takes an average of five days to complete and costs about $2,500 more than standard radiation therapy.

FDA has said that the device has not been proven in clinical trials to replace standard radiation therapy (Kaiser Daily Women's Health Policy Report, 9/14).

According to the Sun-Times, BCBS of Illinois officials said they decided to add the coverage after hearing the recommendations of experts and reviewing "the most current scientific evidence."

Michael Kinney, an Arlington Heights, Ill.-based breast cancer surgeon who had called for BCBS of Illinois to add the coverage, said the decision on whether to use MammoSite can now be "a medical decision, not a financial one" for patients who are covered by the insurer.

Stan Borg, chief medical officer for BCBS of Illinois, said, "It's important to note there is still a level of uncertainty among physicians ... regarding long-term outcomes of this treatment" (Chicago Sun-Times, 9/17).

This article is republished with kind permission from our friends at the The Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, debates and discussions. The Kaiser Daily Health Policy Report is published for Kaisernetwork, a free service of The Henry J. Kaiser Family Foundation. 2006 Advisory Board Company and Kaiser Family Foundation. All rights reserved.